ArticleClinical, cosmetic and investigational dermatology2021
Comparison of SOX-10, HMB-45, and Melan-A in Benign Melanocytic Lesions.
Article in Clinical, cosmetic and investigational dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Comparative study of different treatment modalities for melasma: introducing a novel nanotechnology-based tranexamic acid microemulsion.Archives of dermatological research · 2025Trial
- Cryoblebbing with 5-fluorouracil versus cryoblebbing with melanocyte keratinocyte transplant procedure or cryoblebbing alone in treatment of stable vitiligo.Archives of dermatological research · 2025Trial
- Optimizing Biopsy Decisions in Benign Longitudinal Melanonychia: A Dermoscopic-Pathologic Study of Nail Matrix Nevus vs. Melanocytic Activation.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026Article
- PRAME immunohistochemistry demonstrates high diagnostic accuracy for distinguishing melanoma from nevi but no observed association with pT stage in cutaneous melanoma: a Vietnamese clinicopathological study.Diagnostic pathology · 2026Article
- Polypoid Melanoma: A Rare and Aggressive Variant.Cureus · 2026Article
- Primary adrenal melanoma with extensive metastasis: a case report and literature review.Frontiers in oncology · 2025Article
- The Role of Artificial Intelligence in Early Diagnosis and Molecular Classification of Head and Neck Skin Cancers: A Multidisciplinary Approach.Diagnostics (Basel, Switzerland) · 2024Review
- Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management.International journal of molecular sciences · 2023Review
- Standardized Computer-Assisted Analysis of 5-hmC Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.International journal of molecular sciences · 2023Article
- Dendritic Melanocytic Hyperplasia in Pterygia: A Potential Source of Diagnostic Confusion with Primary Acquired Melanosis.Ocular oncology and pathology · 2023Article
- Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.International journal of molecular sciences · 2023Article
- The Importance of Immunohistochemistry in the Evaluation of Tumor Depth of Primary Cutaneous Melanoma.Diagnostics (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDifferent immunohistochemical stains are used in dermatopathology to stain melanocytes and diagnose benign and malignant melanocytic lesions.
methodsSOX-10, HMB-45, and Melan-A immunohistochemical stains were used to assess 32 biopsy specimens with a histologic diagnosis of lentigo. The total number of melanocytes stained with each immunohistochemical stain was counted and an average count was obtained from two readings.
resultsAnalysis of the data revealed a significant difference in staining melanocytes between these three immunostains (p=0.0010, ANOVA). SOX-10 stained 0.195 more melanocytes than HMB-45 (p=0.0026). Similarly, Melan-A stained 0.195 more melanocytes than HMB-45 (p=0.0011). However, the difference between SOX-10 and Melan-A was not statistically significant (p=0.9810).
conclusionSOX-10 and Melan-A immunostaining stain more melanocytes than HMB-45. No significant difference was noted between Melan-A and SOX-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.